MassMutual Private Wealth & Trust FSB Purchases 782 Shares of Hologic, Inc. $HOLX

MassMutual Private Wealth & Trust FSB lifted its stake in Hologic, Inc. (NASDAQ:HOLX) by 80.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,760 shares of the medical equipment provider’s stock after purchasing an additional 782 shares during the period. MassMutual Private Wealth & Trust FSB’s holdings in Hologic were worth $115,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Zions Bancorporation National Association UT acquired a new stake in shares of Hologic in the first quarter valued at approximately $34,000. Allworth Financial LP grew its holdings in Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock worth $40,000 after acquiring an additional 216 shares during the period. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Hologic during the 1st quarter worth $42,000. Larson Financial Group LLC grew its holdings in Hologic by 6,016.7% during the 1st quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider’s stock worth $45,000 after acquiring an additional 722 shares during the period. Finally, West Financial Advisors LLC bought a new position in shares of Hologic during the first quarter worth $50,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Down 2.8%

Shares of NASDAQ HOLX opened at $66.33 on Friday. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.39. The stock has a market capitalization of $14.75 billion, a P/E ratio of 27.52, a P/E/G ratio of 2.47 and a beta of 0.57. The company has a 50-day moving average price of $66.47 and a 200-day moving average price of $62.75. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.03. The firm had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company’s quarterly revenue was up 1.2% on a year-over-year basis. During the same period in the previous year, the company earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on HOLX. Wall Street Zen cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, September 15th. Morgan Stanley boosted their price objective on shares of Hologic from $65.00 to $69.00 and gave the company an “equal weight” rating in a research report on Thursday, July 31st. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $60.00 to $80.00 in a research report on Wednesday, July 9th. Royal Bank Of Canada raised shares of Hologic from a “sector perform” rating to an “outperform” rating and boosted their price objective for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. Finally, Mizuho set a $75.00 price objective on shares of Hologic in a research report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $79.38.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.